Proteomic approaches to predict bioavailability of fatty acids and their influence on cancer and chronic disease prevention.
A low intake of fish and PUFA and high dietary trans- and SFA are considered to be among the main preventable causes of death. Unfortunately, epidemiological and preclinical studies have yet to identify biomarkers that accurately predict the influence of fatty acid intake on risk of chronic diseases, including cancer. Changes in protein profile and post-translational modifications in tissue and biofluids may offer important clues about the impact of fatty acids on the etiology of chronic diseases. However, conventional protein methodologies are not adequate for assessing the impact of fatty acids on protein expression patterns and modifications and the discovery of protein biomarkers that predict changes in disease risk and progression in response to fatty acid intake. Although fluctuations in protein structure and abundance and inter-individual variability often mask subtle effects caused by dietary intervention, modern proteomic platforms offer tremendous opportunities to increase the sensitivity of protein analysis in tissues and biofluids (plasma, urine) and elucidate the effects of fatty acids on regulation of protein networks. Unfortunately, the number of studies that adopted proteomic tools to investigate the impact of fatty acids on disease risk and progression is quite small. The future success of proteomics in the discovery of biomarkers of fatty acid nutrition requires improved accessibility and standardization of proteomic methodologies, validation of quantitative and qualitative protein changes (e.g., expression levels, post-translational modifications) induced by fatty acids, and application of bioinformatic tools that can inform about the cause-effect relationships between fatty acid intake and health response.
University of Aberdeen, Rowett Institute of Nutrition and Health, Aberdeen, UK. b.deroos@abdn.ac.uk
Baukje
B
de Roos
Donato F
DF
Romagnolo
D001682:Biological Availability; D015415:Biomarkers / Q000378:metabolism; D002908:Chronic Disease / Q000517:prevention & control*; D004032:Diet; D004041:Dietary Fats / Q000009:adverse effects / Q000627:therapeutic use*; D005227:Fatty Acids / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000209:etiology / Q000517:prevention & control*; D011499:Protein Processing, Post-Translational; D020543:Proteome / Q000378:metabolism*; D040901:Proteomics
D015415:Biomarkers; D004041:Dietary Fats; D005227:Fatty Acids; D020543:Proteome